Home › Catalogue › Tirzepatide
Research material

Tirzepatide for laboratory research

A dual GIP and GLP-1 receptor agonist peptide. It is the active ingredient of licensed prescription medicines, so laboratory supply is tightly regulated and reviewed.

Research-use notice: Tirzepatide is listed for legitimate non-clinical laboratory research enquiries only. It is not offered as a medicine, supplement or product for human or veterinary use, and NEXA does not provide dosing or administration information.

Overview

Tirzepatide is a 39-amino-acid synthetic peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It carries a C-20 fatty diacid moiety that promotes albumin binding.

Tirzepatide is the active pharmaceutical ingredient of licensed prescription medicines. NEXA does not supply medicines. Any research material enquiry is assessed against the requesting organisation, its research purpose and the destination country's controls.

Reference identity data

Common nameTirzepatide
ClassDual GIP / GLP-1 receptor agonist (peptide)
Length39 amino acids
Molecular formulaC225H348N48O68
Molecular weight (approx.)4813.5 g/mol
Typical formLyophilised powder (to be confirmed per batch)

Values shown are standard literature reference values. Salt form, net peptide content, purity method and observed mass must be confirmed against the batch Certificate of Analysis.

Documentation available on request

  • Batch-specific Certificate of Analysis, including the testing method, date and issuing laboratory
  • HPLC purity with chromatogram, and mass spectrometry identity with observed and theoretical mass
  • Net peptide content and salt form, where determined
  • Batch number traceable to the vial label and invoice

No purity, testing or stock claim is published without supporting records. Read our guide on how to read a peptide Certificate of Analysis.

Regulatory status and eligibility

As the active ingredient of licensed medicines, tirzepatide is subject to pharmaceutical regulation in many countries. Supply is considered only to qualified organisations, for non-clinical laboratory research, where the destination permits it.

Requests must come from a laboratory or research organisation and describe a legitimate non-clinical research purpose. Personal-use requests are declined. Import requirements in the destination country are the customer's responsibility.

Handling

For storage and handling of lyophilised material in the laboratory, see storing and handling lyophilised peptides.

Related materials